23 - Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up

Notas do episódio

Discussão do artigo: "Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up" de Dimopoulos M Lancet Haematol 2023 Apresentado por: Dra Luana Pompeu Discussão por: Dra. Camila Ferreira, Dr. Matheus Puls, Dr. Gabriel Coquito, Dr. Pedro Arruda, Dr. Vinicius Molla e Dra. Roberta Szor.